The regulation of pharmacy benefit managers (PBMs), the intermediaries in the prescription drug supply chain, took a significant step forward on Wednesday as a key Senate committee advanced bipartisan legislation. The Senate Finance Committee approved the measure by a vote of 25-1, highlighting the broad bipartisan interest in PBM reform. The lone dissenter, Sen. Ron …
The court battle surrounding Medicare’s drug price negotiation program is intensifying as the deadline for determining which drugs will be included approaches. Currently, there are five organizations, including three pharmaceutical companies and two trade groups, that are suing the federal government over the Medicare Drug Price Negotiation Program. This program is an essential component of …
Senator Bernie Sanders (I-Vt.) is currently at odds with the White House regarding drug pricing, causing frustration and confusion among public health experts. They are concerned that his demands may hinder the confirmation of Monica Bertagnolli, the nominee for the National Institutes of Health (NIH) leadership position. Bertagnolli, a respected cancer surgeon and current leader …
The U.S. Chamber of Commerce, known as one of the largest lobbying groups in the country, has taken legal action to prevent the implementation of the Medicare Drug Price Negotiation program, established by the Inflation Reduction Act (IRA). This program has been met with numerous legal challenges, and the Chamber filed a lawsuit last month …
The Centers for Medicare and Medicaid Services (CMS) have announced revisions to their guidance for the Medicare drug price negotiation program, which was established under the Inflation Reduction Act (IRA). These changes appear to be a response to multiple lawsuits challenging the program’s constitutionality. The negotiations for the Medicare Drug Price Negotiation Program are scheduled …
Pharmaceutical companies and House Republicans have come together to launch a comprehensive and aggressive assault on President Joe Biden’s new Medicare drug reforms. These reforms, which have already begun to lower prescription costs for seniors, are considered to be one of Biden’s major accomplishments. However, the pharmaceutical industry and House Republicans argue that these reforms …
Bristol Myers Squibb (BMS), a leading U.S. pharmaceutical company, has joined the growing list of organizations filing a legal challenge against the Medicare drug price negotiation program established by the Inflation Reduction Act (IRA). In line with similar complaints filed by Merck & Co. and the Chamber of Commerce, BMS argues that the provision in …
Antiretroviral drugs have revolutionized the treatment of HIV/AIDS, but their high costs continue to be a barrier for many patients. One factor contributing to these high prices is the exclusion of generic competition through “pay for delay” agreements. Brand-name drug companies pay other companies to delay the introduction of generic equivalents, allowing them to maintain …